"Dextromethorphan Market Summary
According to the latest report published by Data Bridge Market Research, the Dextromethorphan Market
Data Bridge Market Research analyses that the global dextromethorphan market which was USD 487.25 million in 2022, is expected to reach USD 587.31 million by 2030, and is expected to undergo a CAGR of 4.8% during the forecast period of 2023 to...
"Dextromethorphan Market Summary
According to the latest report published by Data Bridge Market Research, the Dextromethorphan Market
Data Bridge Market Research analyses that the global dextromethorphan market which was USD 487.25 million in 2022, is expected to reach USD 587.31 million by 2030, and is expected to undergo a CAGR of 4.8% during the forecast period of 2023 to 2030....
"Dextromethorphan Market Summary
According to the latest report published by Data Bridge Market Research, the Dextromethorphan Market
Data Bridge Market Research analyses that the global dextromethorphan market which was USD 487.25 million in 2022, is expected to reach USD 587.31 million by 2030, and is expected to undergo a CAGR of 4.8% during the forecast period of 2023 to 2030.
An...
Dextromethorphan-quinidine fixed-dose combination (Nuedexta, Avanir/Otsuka) — the first FDA-approved therapy specifically indicated for pseudobulbar affect (PBA) in amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) patients, modulating glutamatergic and sigma-1 receptor signaling while inhibiting CYP2D6 metabolism — creates the most commercially dynamic market segment,...
Arabic
English
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek